Cantor Fitzgerald’s Bristol-Myers Squibb BMY Stock Holding History

Cantor Fitzgerald’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-15,000	Closed	-$848K	–	335
2024 Q4	$848K	Buy	+15,000	New	+$838K	0.02%	94

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Cantor Fitzgerald's BMY Position: Q1 2025 in Review

Cantor Fitzgerald sold out of Bristol-Myers Squibb (BMY) in Q1 2025, closing a stake of 5,437 shares — an estimated $308K sold.

Cantor Fitzgerald first reported a position in BMY in Q2 2022 and held it in 7 quarters. The position peaked at $27.1M in Q2 2022. 2,477 funds tracked by Wall St. Rank hold BMY as of Q1 2025.

Cantor Fitzgerald reported no remaining Bristol-Myers Squibb position as of Q1 2025 after selling out during the quarter.
Cantor Fitzgerald sold 5,437 Bristol-Myers Squibb shares in Q1 2025, an estimated $308K.
Cantor Fitzgerald first reported a position in Bristol-Myers Squibb in Q2 2022 and held it in 7 quarters.
Cantor Fitzgerald's Bristol-Myers Squibb position peaked at $27.1M in Q2 2022.
2,477 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2025.

Based on Cantor Fitzgerald's 13F filing for Q1 2025, filed 15 May 2025.